uBriGene will be participating in the Cell & Gene Meeting on the Mesa, the premier conference for the cell and gene therapy sector, happening from October 7 to 9 in Phoenix, AZ. This event unites senior executives and decision-makers to tackle commercialization challenges and advance transformative research.
uBriGene Biosciences is your bridge from ATMP concept to commercialization. Our CDMO+ services encompass a wide range of offerings, including cell therapy products (CAR-T, TCR-T, NK cells, iPSC, dendritic cells, and macrophages), viral vectors (AAV, LVV, RVV, AdV, and oncolytic viruses), plasmids, and RNA (mRNA, circRNA, acRNA). With extensive experience in manufacturing, QC testing, and regulatory support for ATMPs, we accelerate therapeutic programs from bench to bedside. Our four Centers of Excellence in North America and Asia Pacific, along with over 20 GMP clean room suites, enable us to support global CGT, vaccine, and RNA product development.
Our team members will be available for meetings through the partnering platform. This is a great chance to connect and discuss how our innovative solutions can help overcome current challenges in the sector.
Join us at the Cell & Gene Meeting on the Mesa and be part of this exciting dialogue to drive the future of healthcare. We look forward to seeing you there!
Contact Us | uBriGene right now to speak with our Cell and Gene Therapy professionals to learn how uBriGene's extensive service portfolio can help to accelerate your project.
Join us and be part of the future of ATMPs with uBriGene via our website Your bridge from ATMPs concept to commercialization | uBriGene!
Follow us on LinkedIn and subscribe to our newsletter to stay informed about our latest developments and announcements.
コメント